Zydus Lifesciences Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Zydus Lifesciences Limited generated cash of $32,279,000,000, which is more than the previous year. Cash used in financing activities reached the amount of -$18,104,000,000 last year. Net change in cash is therefore -$748,000,000.
Cash Flow
| 2012 | 5.01B | -11.90B | 8.59B |
|---|---|---|---|
| 2016 | 19.93B | -9.03B | -9.52B |
| 2018 | 9.19B | -9.73B | 515M |
| 2020 | 25.05B | -10.12B | -10.94B |
| 2021 | 32.93B | -7.22B | -25.48B |
| 2023 | 26.88B | 11.71B | -44.00B |
| 2024 | 32.27B | -14.75B | -18.10B |
ZYDUSLIFE.NS Cash Flow Statement (2012 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.87B | 11.06B | 11.77B | 7.78B | 15.92B | 7.90B | 2.95B |
Operating activities | |||||||
Net income | 38.59B | 25.82B | 22.84B | 14.95B | 23.12B | 21.23B | 6.52B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 7.64B | 7.22B | 7.24B | 6.96B | 5.40B | 3.02B | 1.57B |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -7.47B | -8.48B | 4.31B | 5.63B | -9.69B | -1.11B | 0 |
Inventories | -20M | 4.40B | -4.79B | -1.01B | -5.92B | 845M | -2.78B |
Accounts payable | -448M | -1.70B | 1.70B | 564M | 3.16B | 2.57B | 0 |
Cash generated by operating activities | 32.27B | 26.88B | 32.93B | 25.05B | 9.19B | 19.93B | 5.01B |
Investing activities | |||||||
Purchases Of Investments | -4.64B | -2.60B | -400M | -1.85B | 0 | -1M | -1.66B |
Investments In Property Plant And Equipment | -9.06B | -10.30B | -8.54B | -9.04B | -10.49B | -9.71B | -12.44B |
Acquisitions Net | -7.20B | 1.14B | 1.03B | 1.56B | 140M | 54M | 0 |
Cash generated by investing activities | -14.75B | 11.71B | -7.22B | -10.12B | -9.73B | -9.03B | -11.90B |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 9.86B | 0 | 0 | 0 | 0 |
Payments for dividends | -6.21B | -2.67B | -15M | -8.56B | -10M | -5.78B | -1.26B |
Repurchases of common stock | -7.25B | -8.63B | -8.33B | 0 | 0 | 0 | 0 |
Repayments of term debt | -3.92B | -31.47B | -25.68B | -3.48B | 1.57B | -2.01B | -2.90B |
Cash used in financing activities | -18.10B | -44.00B | -25.48B | -10.94B | 515M | -9.52B | 8.59B |
Net Change In Cash | -748M | -5.33B | -905M | 3.98B | -29M | 1.37B | 1.71B |
Cash at end of period | 4.13B | 5.73B | 10.87B | 11.77B | 15.89B | 9.27B | 4.66B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |